Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

The CD26/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity.

Jang JH, Janker F, De Meester I, Arni S, Borgeaud N, Yamada Y, Gil Bazo I, Weder W, Jungraithmayr W.

Carcinogenesis. 2019 Jan 29. doi: 10.1093/carcin/bgz009. [Epub ahead of print]

PMID:
30698677
2.

Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network.

Román M, López I, Guruceaga E, Baraibar I, Ecay M, Collantes M, Nadal E, Vallejo A, Cadenas S, Miguel ME, Jang JH, Martin-Uriz PS, Castro-Labrador L, Vilas-Zornoza A, Lara-Astiaso D, Ponz-Sarvise M, Rolfo C, Santos ES, Raez LE, Taverna S, Behrens C, Weder W, Wistuba II, Vicent S, Gil-Bazo I.

Cancer Res. 2019 Feb 1;79(3):625-638. doi: 10.1158/0008-5472.CAN-18-1479. Epub 2018 Dec 18.

PMID:
30563891
3.

5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging.

Martínez-Terroba E, Behrens C, Agorreta J, Monsó E, Millares L, Felip E, Rosell R, Ramirez JL, Remirez A, Torre W, Gil-Bazo I, Idoate MA, de-Torres JP, Pio R, Wistuba II, Pajares MJ, Montuenga LM.

Thorax. 2018 Nov 24. pii: thoraxjnl-2018-212194. doi: 10.1136/thoraxjnl-2018-212194. [Epub ahead of print]

PMID:
30472670
4.

Improvement of appropriate pharmacological prophylaxis in hospitalised cancer patients with a multiscreen e-alert system: a single-centre experience.

Figueroa R, Alfonso A, López-Picazo J, Gil-Bazo I, García-Mouriz A, Hermida J, Páramo JA, Lecumberri R.

Clin Transl Oncol. 2018 Nov 16. doi: 10.1007/s12094-018-1986-1. [Epub ahead of print]

PMID:
30446983
5.

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.

Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, Davalos V, Piñeyro D, Sanchez-Cespedes M, Girard N, Brevet M, Giroux-Leprieur E, Dumenil C, Pradotto M, Bironzo P, Capelletto E, Novello S, Cortot A, Copin MC, Karachaliou N, Gonzalez-Cao M, Peralta S, Montuenga LM, Gil-Bazo I, Baraibar I, Lozano MD, Varela M, Ruffinelli JC, Palmero R, Nadal E, Moran T, Perez L, Ramos I, Xiao Q, Fernandez AF, Fraga MF, Gut M, Gut I, Teixidó C, Vilariño N, Prat A, Reguart N, Benito A, Garrido P, Barragan I, Emile JF, Rosell R, Brambilla E, Esteller M.

Lancet Respir Med. 2018 Oct;6(10):771-781. doi: 10.1016/S2213-2600(18)30284-4. Epub 2018 Aug 9.

PMID:
30100403
6.

Insights into venous thromboembolism prevention in hospitalized cancer patients: Lessons from a prospective study.

Figueroa R, Alfonso A, López-Picazo J, Gil-Bazo I, García-Mouriz A, Hermida J, Páramo JA, Lecumberri R.

PLoS One. 2018 Aug 2;13(8):e0200220. doi: 10.1371/journal.pone.0200220. eCollection 2018.

7.

Targeted DNA sequencing for assessing clonality in multiple lung tumors: A new approach to an old dilemma.

Eguren-Santamaria I, Sanchez-Bayona R, Patiño-Garcia A, Gil-Bazo I, Lopez-Picazo JM.

Lung Cancer. 2018 Aug;122:120-123. doi: 10.1016/j.lungcan.2018.05.029. Epub 2018 Jun 1.

PMID:
30032819
8.

Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer.

Fusco JP, Pita G, Pajares MJ, Andueza MP, Patiño-García A, de-Torres JP, Gurpide A, Zulueta J, Alonso R, Alvarez N, Pio R, Melero I, Sanmamed MF, Rodriguez Ruiz M, Gil-Bazo I, Lopez-Picazo JM, Casanova C, Baz Davila R, Agudo A, Lozano MD, Gonzalez A, Sala N, Ardanaz E, Benitez J, Montuenga L, Gonzalez-Neira A, Perez-Gracia JL.

Cancer Med. 2018 May 15. doi: 10.1002/cam4.1500. [Epub ahead of print]

9.

Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients.

Rodríguez-Ruiz ME, Perez-Gracia JL, Rodríguez I, Alfaro C, Oñate C, Pérez G, Gil-Bazo I, Benito A, Inogés S, López-Diaz de Cerio A, Ponz-Sarvise M, Resano L, Berraondo P, Barbés B, Martin-Algarra S, Gúrpide A, Sanmamed MF, de Andrea C, Salazar AM, Melero I.

Ann Oncol. 2018 May 1;29(5):1312-1319. doi: 10.1093/annonc/mdy089.

PMID:
29554212
10.

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.

Román M, Baraibar I, López I, Nadal E, Rolfo C, Vicent S, Gil-Bazo I.

Mol Cancer. 2018 Feb 19;17(1):33. doi: 10.1186/s12943-018-0789-x. Review.

11.

Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment.

Passiglia F, Caglevic C, Giovannetti E, Pinto JA, Manca P, Taverna S, Listì A, Gil-Bazo I, Raez LE, Russo A, Rolfo C.

Semin Cancer Biol. 2018 Oct;52(Pt 2):259-268. doi: 10.1016/j.semcancer.2018.01.015. Epub 2018 Jan 31. Review.

PMID:
29391205
12.

Avelumab-a new programmed death-ligand 1 inhibitor against advanced non-small cell lung cancer.

Gil-Bazo I.

Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S35-S38. doi: 10.21037/tlcr.2017.11.01. No abstract available.

13.

Endovascular treatment of malignant superior vena cava syndrome secondary to lung cancer.

Calsina Juscafresa L, Gil Bazo I, Grochowicz L, Páramo Alfaro M, López-Picazo González JM, Moreno Jiménez M, Bilbao Jaureguizar JI.

Hosp Pract (1995). 2017 Aug;45(3):70-75. doi: 10.1080/21548331.2017.1342507. Epub 2017 Jun 26.

PMID:
28618844
14.

Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathway.

Taverna S, Pucci M, Giallombardo M, Di Bella MA, Santarpia M, Reclusa P, Gil-Bazo I, Rolfo C, Alessandro R.

Sci Rep. 2017 Jun 9;7(1):3170. doi: 10.1038/s41598-017-03460-y.

15.

Plasma rich in growth factors for the treatment of rapidly progressing refractory corneal melting due to erlotinib in nonsmall cell lung cancer.

Guarnieri A, Alfonso-Bartolozzi B, Ciufo G, Moreno-Montañés J, Gil-Bazo I.

Medicine (Baltimore). 2017 Jun;96(22):e7000. doi: 10.1097/MD.0000000000007000.

16.

The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment of the pre-metastatic niche.

Castañón E, Soltermann A, López I, Román M, Ecay M, Collantes M, Redrado M, Baraibar I, López-Picazo JM, Rolfo C, Vidal-Vanaclocha F, Raez L, Weder W, Calvo A, Gil-Bazo I.

Cancer Lett. 2017 Aug 28;402:43-51. doi: 10.1016/j.canlet.2017.05.012. Epub 2017 May 24.

PMID:
28549790
17.

Pazopanib-induced asymptomatic radiological acute pancreatitis: A case report.

Baraibar I, Quílez A, Salas D, Román M, Rolfo C, Pérez-Gracia JL, Gil-Bazo I.

Mol Clin Oncol. 2017 May;6(5):651-654. doi: 10.3892/mco.2017.1210. Epub 2017 Apr 6.

18.

Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.

Alegre E, Fusco JP, Restituto P, Salas-Benito D, Rodríguez-Ruiz ME, Andueza MP, Pajares MJ, Patiño-García A, Pio R, Lozano MD, Gúrpide A, Lopez-Picazo JM, Gil-Bazo I, Perez-Gracia JL, Gonzalez A.

Tumour Biol. 2016 Oct;37(10):13687-13694. Epub 2016 Jul 29.

PMID:
27473086
19.

The present and the future of the RAS pathway: From function and genomics to inhibition.

Gil-Bazo I, Sweet-Cordero A, Vicent S.

Cancer Biol Ther. 2016 Jul 2;17(7):719-22. doi: 10.1080/15384047.2016.1190487. Epub 2016 May 21.

20.

BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?

Caparica R, de Castro G Jr, Gil-Bazo I, Caglevic C, Calogero R, Giallombardo M, Santos ES, Raez LE, Rolfo C.

Crit Rev Oncol Hematol. 2016 May;101:32-9. doi: 10.1016/j.critrevonc.2016.02.012. Epub 2016 Feb 27. Review.

21.

AZD9291 in TKI EGFR resistance in non-small cell lung cancer and the new concept of phase I trials.

Gil-Bazo I, Rolfo C.

Transl Lung Cancer Res. 2016 Feb;5(1):85-8. doi: 10.3978/j.issn.2218-6751.2015.07.02.

22.

Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice.

Taverna S, Giallombardo M, Gil-Bazo I, Carreca AP, Castiglia M, Chacártegui J, Araujo A, Alessandro R, Pauwels P, Peeters M, Rolfo C.

Oncotarget. 2016 May 10;7(19):28748-60. doi: 10.18632/oncotarget.7638. Review.

23.

Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.

Azpilikueta A, Agorreta J, Labiano S, Pérez-Gracia JL, Sánchez-Paulete AR, Aznar MA, Ajona D, Gil-Bazo I, Larrayoz M, Teijeira A, Rodriguez-Ruiz ME, Pio R, Montuenga LM, Melero I.

J Thorac Oncol. 2016 Apr;11(4):524-36. doi: 10.1016/j.jtho.2016.01.013. Epub 2016 Feb 1.

24.

Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes.

Olarte A, Cambeiro M, Moreno-Jiménez M, Arbea L, Pérez-Gracia JL, Gil-Bazo I, Pascual I, Aristu J, Martínez-Monge R.

Brachytherapy. 2016 Mar-Apr;15(2):127-35. doi: 10.1016/j.brachy.2015.12.008. Epub 2016 Jan 29.

PMID:
26832677
25.

Safety and efficacy of temsirolimus under compassionate use in heavily pretreated patients with poor-prognosis solid tumors.

Fusco JP, Rolfo C, Castañón E, Ceniceros L, Legaspi J, Espinós J, Rodríguez J, Aramendía JM, Santisteban M, Gil-Bazo I.

Minerva Chir. 2015 Dec;70(6):495-8. No abstract available.

PMID:
26657760
26.

Stereotactic body radiation therapy (SBRT) delays the emergence of castration resistance in patients with oligometastatic prostate cancer.

Martínez-Fernández MI, Pérez Gracia JL, Gil-Bazo I, Martínez-Monge R.

Clin Transl Oncol. 2016 Jul;18(7):743-7. doi: 10.1007/s12094-015-1414-8. Epub 2015 Oct 19.

PMID:
26482722
27.

Factors influencing the use of thromboprophylaxis in cancer outpatients in clinical practice: A prospective study.

Panizo E, Alfonso A, García-Mouriz A, López-Picazo JM, Gil-Bazo I, Hermida J, Páramo JA, Lecumberri R.

Thromb Res. 2015 Dec;136(6):1145-8. doi: 10.1016/j.thromres.2015.10.015. Epub 2015 Oct 9.

PMID:
26475407
28.

Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.

Rolfo C, Ruiz R, Giovannetti E, Gil-Bazo I, Russo A, Passiglia F, Giallombardo M, Peeters M, Raez L.

Expert Opin Investig Drugs. 2015;24(11):1493-500. doi: 10.1517/13543784.2015.1096344. Epub 2015 Oct 12. Review.

PMID:
26457764
29.

Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis.

Castañón E, Rolfo C, Viñal D, López I, Fusco JP, Santisteban M, Martin P, Zubiri L, Echeveste JI, Gil-Bazo I.

J Transl Med. 2015 Aug 7;13:257. doi: 10.1186/s12967-015-0622-x.

30.

Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients.

Ceniceros L, Aristu J, Castañón E, Rolfo C, Legaspi J, Olarte A, Valtueña G, Moreno M, Gil-Bazo I.

Clin Transl Oncol. 2016 Mar;18(3):259-68. doi: 10.1007/s12094-015-1361-4. Epub 2015 Aug 5. Review.

PMID:
26243396
31.

Suppression of lung metastases by the CD26/DPP4 inhibitor Vildagliptin in mice.

Jang JH, Baerts L, Waumans Y, De Meester I, Yamada Y, Limani P, Gil-Bazo I, Weder W, Jungraithmayr W.

Clin Exp Metastasis. 2015 Oct;32(7):677-87. doi: 10.1007/s10585-015-9736-z. Epub 2015 Aug 2.

PMID:
26233333
32.

What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis.

Bronte G, Rolfo C, Passiglia F, Rizzo S, Gil-Bazo I, Fiorentino E, Cajozzo M, Van Meerbeeck JP, Lequaglie C, Santini D, Pauwels P, Russo A.

Crit Rev Oncol Hematol. 2015 Sep;95(3):306-17. doi: 10.1016/j.critrevonc.2015.03.010. Epub 2015 Apr 11. Review.

PMID:
25922216
33.

Nintedanib in non-small cell lung cancer: from preclinical to approval.

Caglevic C, Grassi M, Raez L, Listi A, Giallombardo M, Bustamante E, Gil-Bazo I, Rolfo C.

Ther Adv Respir Dis. 2015 Aug;9(4):164-72. doi: 10.1177/1753465815579608. Epub 2015 Apr 7. Review.

PMID:
25855060
34.

cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance.

Van Der Steen N, Pauwels P, Gil-Bazo I, Castañon E, Raez L, Cappuzzo F, Rolfo C.

Cancers (Basel). 2015 Mar 25;7(2):556-73. doi: 10.3390/cancers7020556. Review.

35.

ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.

Rolfo C, Passiglia F, Castiglia M, Raez LE, Germonpre P, Gil-Bazo I, Zwaenepoel K, De Wilde A, Bronte G, Russo A, Van Meerbeeck JP, Van Schil P, Pauwels P.

Transl Lung Cancer Res. 2014 Aug;3(4):250-61. doi: 10.3978/j.issn.2218-6751.2014.03.01. Review.

36.

Looking into the "Garden of the Hesperides": new drugs for hepatocellular carcinoma.

Castañón Alvarez E, Giallombardo M, Gil-Bazo I, Papadimitriou K, Pauwels P, Peeters M, Rolfo C.

Minerva Chir. 2015 Apr;70(2):119-29. Epub 2015 Jan 23. Review.

PMID:
25614940
37.

Pneumomediastinum as a complication of SABR for lung metastases.

Rodríguez-Ruiz ME, Arévalo E, Gil-Bazo I, Olarte García A, Valtueña G, Moreno-Jiménez M, Arbea-Moreno L, Aristu J.

Radiat Oncol. 2015 Jan 23;10:25. doi: 10.1186/s13014-015-0330-y.

38.

The role of cMet in non-small cell lung cancer resistant to EGFR-inhibitors: did we really find the target?

Passiglia F, Van Der Steen N, Raez L, Pauwels P, Gil-Bazo I, Santos E, Santini D, Tesoriere G, Russo A, Bronte G, Zwaenepoel K, Cappuzzo F, Rolfo C.

Curr Drug Targets. 2014;15(14):1284-92. Review.

PMID:
25511614
39.

Epidermal Growth Factor Receptor targeting in non-small cell lung cancer: revisiting different strategies against the same target.

Castañón E, Martín P, Rolfo C, Fusco JP, Ceniceros L, Legaspi J, Santisteban M, Gil-Bazo I.

Curr Drug Targets. 2014;15(14):1273-83. Review.

PMID:
25511613
40.

Cancer and the microbiome: potential applications as new tumor biomarker.

Shahanavaj K, Gil-Bazo I, Castiglia M, Bronte G, Passiglia F, Carreca AP, del Pozo JL, Russo A, Peeters M, Rolfo C.

Expert Rev Anticancer Ther. 2015 Mar;15(3):317-30. doi: 10.1586/14737140.2015.992785. Epub 2014 Dec 15. Review.

PMID:
25495037
41.

The inhibitor of differentiation isoform Id1b, generated by alternative splicing, maintains cell quiescence and confers self-renewal and cancer stem cell-like properties.

Manrique I, Nguewa P, Bleau AM, Nistal-Villan E, Lopez I, Villalba M, Gil-Bazo I, Calvo A.

Cancer Lett. 2015 Jan 28;356(2 Pt B):899-909. doi: 10.1016/j.canlet.2014.10.035. Epub 2014 Nov 6.

PMID:
25449776
42.

Liquid biopsies in lung cancer: the new ambrosia of researchers.

Rolfo C, Castiglia M, Hong D, Alessandro R, Mertens I, Baggerman G, Zwaenepoel K, Gil-Bazo I, Passiglia F, Carreca AP, Taverna S, Vento R, Santini D, Peeters M, Russo A, Pauwels P.

Biochim Biophys Acta. 2014 Dec;1846(2):539-46. doi: 10.1016/j.bbcan.2014.10.001. Epub 2014 Oct 16. Review. Erratum in: Biochim Biophys Acta. 2015 Jan; 1855(1):17. Santini, Daniele [added].

PMID:
25444714
43.

Myopathy in hereditary leiomyomatosis and renal cell cancer in an extended family.

España A, Ornilla E, Zarate R, Gil-Bazo I, Briones P.

Br J Dermatol. 2015;172(5):1442-5. doi: 10.1111/bjd.13504. Epub 2015 Mar 11. No abstract available.

PMID:
25354562
44.

Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors.

Rolfo C, Giovannetti E, Hong DS, Bivona T, Raez LE, Bronte G, Buffoni L, Reguart N, Santos ES, Germonpre P, Taron M, Passiglia F, Van Meerbeeck JP, Russo A, Peeters M, Gil-Bazo I, Pauwels P, Rosell R.

Cancer Treat Rev. 2014 Sep;40(8):990-1004. doi: 10.1016/j.ctrv.2014.05.009. Epub 2014 Jun 6. Review.

PMID:
24953979
45.

Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed.

Arévalo E, Castañón E, López I, Salgado J, Collado V, Santisteban M, Rodríguez-Ruiz M, Martín P, Zubiri L, Patiño-García A, Rolfo C, Gil-Bazo I.

J Transl Med. 2014 Apr 14;12:98. doi: 10.1186/1479-5876-12-98.

46.

Differential tumor expression of inhibitor of differentiation-1 in prostate cancer patients with extreme clinical phenotypes and prognostic implications.

Ponz-Sarvisé M, Castañón E, Panizo-Santos A, Redrado M, López I, Rosell D, Gil-Aldea I, Calvo A, Nguewa PA, Gil-Bazo I.

Clin Genitourin Cancer. 2014 Apr;12(2):87-93. doi: 10.1016/j.clgc.2013.08.007. Epub 2013 Oct 12.

PMID:
24129125
47.

Neurological and cytological response as potential early predictors of time-to-progression and overall survival in patients with leptomeningeal carcinomatosis treated with intrathecal liposomal cytarabine: a retrospective cohort study.

Fusco JP, Castañón E, Carranza OE, Zubiri L, Martín P, Espinós J, Rodríguez J, Santisteban M, Aramendía JM, Gil-Bazo I.

J Neurooncol. 2013 Dec;115(3):429-35. doi: 10.1007/s11060-013-1241-0. Epub 2013 Sep 15.

PMID:
24037499
48.

High incidence of venous thromboembolism despite electronic alerts for thromboprophylaxis in hospitalised cancer patients.

Lecumberri R, Marqués M, Panizo E, Alfonso A, García-Mouriz A, Gil-Bazo I, Hermida J, Schulman S, Páramo JA.

Thromb Haemost. 2013 Jul;110(1):184-90. doi: 10.1160/TH13-02-0131. Epub 2013 May 16.

PMID:
23677515
49.

Spatial-temporal protein expression of inhibitor of differentiation-1 (Id1) during fetal embryogenesis and in different mouse and human cancer types.

Redrado M, Bodegas E, Villaro AC, Nguewa PA, Lopez I, Gil-Bazo I, Calvo A.

Histol Histopathol. 2013 Aug;28(8):1029-40. doi: 10.14670/HH-28.1029. Epub 2013 Apr 5.

PMID:
23558671
50.

Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy.

Castañon E, Bosch-Barrera J, López I, Collado V, Moreno M, López-Picazo JM, Arbea L, Lozano MD, Calvo A, Gil-Bazo I.

J Transl Med. 2013 Jan 11;11:13. doi: 10.1186/1479-5876-11-13.

Supplemental Content

Loading ...
Support Center